Fulminant rebound of relapsing–remitting multiple sclerosis after discontinuation of dimethyl fumarate: A case report. (July 2018)

• Record Type: Journal Article
• Authors: Harmel, Peter; Schlunk, Frieder; Harms, Lutz
• Is Part Of: Multiple sclerosis. Volume 24:Number 8(2018)
• Page Start: 1131
• Page End: 1133
• Publication Date: 2018-07
• Subjects: Multiple sclerosis -- dimethyl fumarate discontinuation -- dimethyl fumarate cessation -- clinical rebound; Central nervous system -- Diseases -- Periodicals; Myelin sheath -- Diseases -- Periodicals; Inflammation -- Periodicals; Multiple sclerosis -- Periodicals; Central Nervous System Diseases -- Periodicals; Demyelinating Diseases -- Periodicals; Inflammation -- Periodicals; Multiple Sclerosis -- Periodicals; Système nerveux central -- Maladies -- Périodiques; Gaine de myéline -- Maladies -- Périodiques; Inflammation (Pathologie) -- Périodiques; Sclérose en plaques -- Périodiques; Electronic journals; 616.834005
• DOI: 10.1177/1352458517741191
• Languages: English
• ISSNs: 1352-4585

Abstract

Background: Rebound phenomena after discontinuation of different treatments for relapsing–remitting multiple sclerosis (RRMS) have previously been described. Systematic database research in PubMed did not show any report with relapse directly associated with dimethyl fumarate (DMF) cessation. Case presentation: Here, we report on a 38-year-old Caucasian male patient suffering from a relatively mild course of RRMS who developed a fulminant clinical rebound 2 months after discontinuation of DMF therapy. Radiological alterations presented impressively with primarily spinal involvement. The patient received intensive care and multiple immunomodulating therapies. Conclusion: We report on this case to raise neurologist's awareness of complications of basic therapy discontinuation in RRMS.